Insider Almenoff June Sherie Buys 30,000 Zero‑Price Options on Tenax Therapeutics as Market Scrutinizes Pulmonary Hypertension Pipeline

Insider Buying Signals a Bet on Tenax’s Pulmonary Hypertension Pipeline On January 9, 2026, director Almenoff June Sherie purchased 30,000 stock‑options at $0.00 exercise price, coinciding with the company’s share price of $15.05. The buy, recorded a day after a modest 0.02 % price rise, comes amid a surge in social‑media buzz (156 % intensity) and a strongly negative sentiment score of –61, suggesting that the broader market remains wary of Tenax’s valuation. Yet the insider action indicates confidence that the company’s ongoing clinical work on levosimendan‑based therapy for PH‑HFPf will eventually translate into earnings growth.

What the Transaction Means for Investors Tenax’s market cap of roughly $540 million and a negative P/E of –11.59 paint a picture of a biotech still in development mode. The insider buy of options—effectively a long‑term bet that the stock will rise—offers a hedge against the company’s current lack of profitability. For investors, this move can be read as a subtle endorsement of Tenax’s clinical roadmap and the potential for a valuation lift once data are published. However, the high social‑media buzz and negative sentiment may continue to weigh on short‑term pricing, so a cautious, long‑term perspective is warranted.

Almenoff June Sherie: A Profile of Opportunistic Stakeholder Sherie’s transaction history shows a pattern of accruing and holding large option positions: 4 options in 2022, 4 in 2023, 80 000 options in July 2025, and 100 000 in December 2025. The recent 30 000‑option purchase follows a series of sizable option acquisitions, suggesting a strategy focused on accumulating upside potential while minimizing upfront capital outlay. The fact that she has repeatedly purchased options at zero exercise price indicates reliance on the company’s future valuation appreciation rather than immediate cash flows—a typical approach for biotech insiders who believe in a breakthrough product.

Implications for Tenax’s Future If the company’s clinical trials for levosimendan succeed, Tenax could see a sharp uptick in earnings, which would likely trigger a reevaluation by the market. The insider option purchases create a built‑in upside for shareholders, potentially aligning the interests of management and investors. Yet the negative earnings and high volatility underscore the risks inherent in a specialty pharma pipeline. Investors should monitor upcoming trial results, regulatory milestones, and any shifts in the company’s pricing strategy, as these will be pivotal in determining whether the insider confidence translates into tangible shareholder value.